Vistagen Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Jun 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 15, 2026
VTGN$0.18-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Year EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenues: | ||
| Sublicense and other revenue | $1,269 | $486 |
| Total revenues | 1,269 | 486 |
| Operating expenses: | ||
| Research and development | 54,974 | 39,375 |
| General and administrative | 18,421 | 17,084 |
| Total operating expenses | 73,395 | 56,459 |
| Loss from operations | (72,126) | (55,973) |
| Other income, net: | ||
| Interest income, net | 2,441 | 4,557 |
| Other income, net | 7 | 5 |
| Loss before income taxes | (69,678) | (51,411) |
| Income taxes | (7) | (7) |
| Net loss | $(69,685) | $(51,418) |
| Unrealized gain (loss) on marketable securities | $(7) | $5 |
| Comprehensive loss | $(69,692) | $(51,413) |
| Basic and diluted net loss per common share | $(1.83) | $(1.67) |
| Weighted average common shares outstanding, basic and diluted | 38,073,926 | 30,877,029 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.